Quick reference guide Issue date: January 2010 Venous thromboembolism: reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism)…

PL Detail-Document #271001 −This PL Detail-Document gives subscribers additional insight related to the Recommendations published in− PHARMACIST’S LETTER / PRESCRIBER’S…

Generic Name: phytonadione Brand Name: Vitamin K Classification: Antidote, Vitamins Date Ordered: july, 30 Ordered Dose: 1 amp IVTT now @ 9pm Suggested Dose: 120 micrograms…

1. ATRIAL FIBRILLATIONDr SYED RAZA MD,MRCP(UK),CCT(UK),MESC,Dip.Card(UK),FCCPConsultant Cardiologist 2. OBJECTIVES• Introduction• Classification• Burden of the problem•…

DABIGATRAN (Evidence from RELY & RELYABLE Trial) & Novel Oral Anticoagulants (NOAC) Dr. Surinder Hansra MD, DNB (Card) FSCAI AF & Stroke • AF increases the…

Pradaxa® (Dabigatran Etexilate) Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc FDA Approved Date: October 15, 2010 Pradaxa®/dabigatran etexilate Date despre medicament…

OP-EHEA200574 1..79acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force for the management of acute coronary syndromes in

Dabigatran, Rivaroxaban, Apixaban and Edoxaban for Deep Vein Thrombosis/Pulmonary Embolism295FM.2 DABIGATRAN, RIVAROXABAN, APIXABAN AND EDOXABAN FOR DEEP VEIN THROMBOSIS